Huisgen's azide-alkyne cycloaddition reaction was employed to synthesize a series of 1H-1,2,3-triazole-tethered uracil-ferrocenyl chalcone conjugates with the aim of evaluating their in vitro anti-proliferative efficacy on human leukemia (CCRF-CEM) and human breast adenocarcinoma (MDA-MB-468) cell lines. Cytotoxic evaluation studies identified a number of synthesized conjugates that inhibited the proliferation of leukemia cancer cells by~70% after 72 h. The selected synthesized conjugates were found to be significantly less cytotoxic against normal kidney cell line (LLC-PK1) when compared with CCRF-CEM cancer cells.
Introduction
Cancer, an uncontrolled growth and rapid proliferation of abnormal cells, is one of the most formidable challenges in the world (Fadeyi et al. 2008) . Most cancers are recognized by the uninhibited growth of cells without demarcation due to the deregulation of crucial enzymes and proteins controlling cell division and proliferation (Mareel and Leroy 2003; Wesche et al. 2011 ). According to the World Health Organization (WHO) report, 8.2 million people died of cancer all over the world in 2016 (https://www.cancer.org/ research/cancer-facts-statistics.html). A recent survey by American Cancer Society of epidemiologists revealed that out of 595,690 cancer deaths in the US, 188,800 was because of cigarette smoking. In addition, 20% of all cancers are associated with body fatness, physical inactivity, excess alcohol consumption, and/or poor nutrition while certain cancers are related to infections caused by human papillomavirus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and Helicobacter pylori. Although much progress has aspired from the diagnosis to the treatment of cancer, the factors like poor patient compliance, drug resistance, and drug-induced toxicities have provided a strong impetus for the discovery and development of novel cancer chemotherapeutic agents of clinical significance (Grant 2009; Solyanik 2011; Vijayaraghavalu et al. 2012) .
The recognition of ferrocene and its derivatives for biological explorations may be ascribed to their stability in aqueous and aerobic media, aptness of derivatization, and appropriate electrochemical properties (Allardyce et al. 2005; Fouda et al. 2007 ). The anticancer activities of ferrocene derivatives were first reported by Fiorina and coworkers against lymphocytic leukemia P-388 (Fiorina et al. 1978) . Ferrocene derivative of the anti-estrogen tamoxifen has also displayed interesting antiproliferative properties, which have been attributed to its redox behavior (Hillard et al. 2006; Hillard et al. 2006; Duivenvoorden et al. 2005) .
The anticancer activities of 2-ferrocenyl-1,1-diphenylbut-1-ene against HL-60, HCT-8, SF-295, MDA-MB-435, OVCAR-8 and GBM non-cancerous cells were reported by de Oliveira and co-workers, (Oliveira et al. 2014) suggesting the potential of conjugating ferrocene with other anticancer agents. A series of ferrocenylcatechol conjugates were synthesized by Tan and coworkers and evaluated for their cytotoxicity against MDA-MB-231 cancer cell lines. The conjugates exhibited better anticancer activities (IC 50 = 0.48-1.21 μM) compared to their corresponding phenolic analogs (0.57-12.70 μM) (Tan et al. 2012) . One of the privileged structures in drug discovery is uracil that has diverse pharmacological profiles, synthetic accessibility, and the ability to bestow drug-like properties to the compound libraries appended to them (Newkome and Pandler 1982) . 5-Fluorouracil (5-FU), an anti-metabolism drug, is widely used in the treatment of malignancies, such as colorectal, stomach and breast cancer. However, its poor selectivity along with high incidences of bone marrow, gastrointestinal tract, and central nervous toxicity has limited its therapeutic importance (Pan et al. 2011) . To address these problems, modifications of 5-FU have been accomplished resulting in the development of 5-FU derivatives viz. floxuridine and tegafur exhibiting improved pharmacological and pharmacokinetic properties (Ohwada et al. 2004) . 5-FU-Camptothecin (CPT) conjugate, a topoisomerase cytotoxic alkaloid has exhibited comparable cytotoxicity to irinotecan (semi-synthetic analog of CPT) with enhanced selectivity, efficacy and safety (Li et al. 2012) .
The prevalence of chalcones as a major constituent or a substituent in varied biologically active compounds represent another important structural motif, synthetically manoeuvered for the development of efficacious drugs against tropical diseases and cancer (Singh et al. 2014) . Chalcones have congregated considerable attention for their cytotoxic activities because of their similar mode of action to the structurally related combretastatin (Pettit et al. 2005) . Chalcone is considered a promising template for the development of HIF-1 inhibitors, a major mechanism for the survival and evasion of tumor cells (Srinivasan et al. 2011) .
The recent revelation from our laboratory has shown the synthesis and cytotoxic potential of 1H-1,2,3-triazole-tethered β-lactam-chalcone conjugates with activity mainly dependent upon the nature of substituents present at aryl rings of chalcone as well as at N-1 position of the β-lactam ring . In continuation of our efforts for the synthesis of biologically relevant heterocycles using molecular hybridization, (Singh et al. 2017; Raj et al. 2015; Kumar et al. 2012; , Singh et al. 2014 ) the present work describes the synthesis of uracil-ferrocenyl chalcone conjugates, along with an evaluation of their in vitro antiproliferative efficacy on human leukemia (CCRF-CEM,) and human breast adenocarcinoma (MDA-MB-468) cell lines.
Experimental section
Melting points were determined by an open capillary using a Veego Precision Digital Melting Point apparatus (MP-D) and are uncorrected.
1 H NMR spectra were recorded in dimethyl sulfoxide (DMSO) with a BRUKER AVANCE II (500 MHz) spectrometer using TMS as an internal standard. Chemical shift values are expressed as parts per million downfield from TMS and J values are in hertz. Splitting patterns are indicated as s: singlet, d: doublet, t: triplet, m: multiplet, dd: double doublet, ddd: doublet of a doublet of a doublet, and br: broad peak.
13
C NMR spectra were recorded in DMSO with a BRUKER AVANCE II (125 MHz) using TMS as internal standard. Mass spectra were recorded on a BRUCKER high-resolution mass spectrometer (micrOTOF-QII). Elemental analyses were performedon a Heraus CHN-O-Rapid Elemental Analyzer. Column chromatography was performed on silica gel (60-120 mesh) using ethyl chloroform:hexane mixture as eluent.
General procedure for the synthesis of uracil-ferrocenyl chalcone conjugates (5a-r)
To a stirred solution of O-propargylated ferrocenylchalcone 4 (1 mmol) and N-alkylated-azido-uracil 3 (1 mmol) in an ethanol:water mixture was added copper sulfate (0.05 mmol) and sodium ascorbate (0.13 mmol). The reaction mixture was allowed to stir at room temperature for 10 −12 h, and the progress was monitored using TLC. After the completion of reaction, water (20 mL) was added, and the reaction mixture was extracted twice with dichloromethane (2 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield a crude product, which was purified via column chromatography using a 5:95 (methanol:chloroform, v/v) mixture. 48.5, 61.7, 69.0, 69.7, 71.4, 84.8, 102.1, 114.6, 114.7, 118.8, 125.0, 130.5, 143.2, 144.6, 145.7, 150.3, 159.8, 163.9, 187.7 C, 60.99; H, 4.57; N, 12.70: C, 60.82; H, 4.62; N, 12.66 . 45.5, 47.4, 61.8, 69.6, 69.9, 71.5, 79.7, 101.6, 115.1, 119.3, 125.2, 131.0, 131.4, 142.7, 145.7, 145.9, 151.4, 162.1, 164.2, 187. 25.7, 27.2, 47.6, 49.5, 61.5, 69.5, 69.8, 71.3, 79.6, 101.3, 115.4, 119.4, 125.0, 131.1,131.2, 142.8, 145.7, 150.5, 160.5, 162.4, 187 23.3, 28.4, 29.3, 48.3, 49.4, 61.6, 69.7, 69.8, 71.4, 79.5, 101.1, 115.2, 119.2, 125.1, 131.2, 131.3, 142.7, 145.4, 150.4, 160.3, 162.3, 187.2 29.6, 48.2, 49.3, 61.6, 69.5, 69.6, 71.3, 79.3, 101.2, 115.3, 119.3, 125.2, 131.2, 131.3, 142.7, 145.7, 146.1, 150.3, 160.2, 162.6, 187.4 45.3, 47.5, 61.7, 69.5, 69.6, 71.4, 79.5, 105.4, 115.3, 119.4, 125.4, 131.2, 131.5, 142.5, 145.5, 145.8, 151.6, 162.3, 164.5, 187 25.8, 27.3, 47.5, 49.3, 61.7, 69.3, 69.7, 71.4, 79.5, 105.6, 115.3, 119.5, 125.3, 131.2, 131.3, 142.4, 145.5, 150.7, 160.3, 162.5, 187 28.3, 29.5, 48.2, 49.3, 61.5, 69.4, 69.5, 71.3, 79.4, 105.2, 115.3, 119.4, 125.2, 131.1, 131.3, 142.5, 145.6, 150.6, 160.4, 162.3, 187. 25.3, 28.4, 29.3, 48.4, 49.5, 61.4, 69.3, 69.4, 71.5, 79.5, 106.2, 115.4, 119.5, 125.4, 131.4, 131.6, 142.2, 145.5, 146.3, 150.1, 160.4, 162.3 26.3, 28.3, 28.5, 28.8, 30.2, 47.5, 49.6, 61.7, 69.3, 69.7, 71.3, 79.4, 106.4, 115.3, 119.1, 125.4, 131.2, 131.5, 142.4, 145.2, 146.3, 151.6, 162.3, 164.3, 187.4 H, 5.42; N, 10.15. Found: C, 61.87; H, 5.32; N, 10.07 . 48.0, 48.2, 61.7, 61.8, 69.8, 71.4, 79.3, 95.8, 114.7, 118.9, 125.0, 130.6, 131.5, 143.1, 144.5, 145.6, 150.5, 159.9, 161.8, 187 C, 53.36; H, 3.84; N, 11.11; Found: C, 53.41; H, 3.78; N, 
base-promoted propargylation of p-hydroxyacetophenone, followed by its condensation with ferrocenecarboxaldehyde in ethanol as reported previously . The second precursor viz. N-alkylazido 5-substituted uracil derivatives were prepared by hydridepromoted alkylation of 5-substituted uracil analogs with dibromoalkane followed by its nucleophilic substitution reaction with sodium azide. Mono-alkylated uracil is accompanied by the formation of dialkylated uracils albeit in poor yields as per literary reports (Dezor-Mazur et al. 1984) . Cu-promoted azide-alkyne cycloaddition reaction between N-alkyl azido-uracils and O-propargylated ferrocenyl-chalcone afforded the desired 1H-1,2,3-triazoletethered uracil-ferrocenyl chalcone conjugates that were purified via column chromatography using CHCl 3 :CH 3 OH (95:5 v/v) mixture as the eluents (Scheme 1). The structures of the synthesized uracil-ferrocenyl chalcone conjugates were assigned on the basis of spectral data and analytical evidence. The conjugate 5p, for example, showed a molecular ion peak at 671.0831 (m/z) along with a characteristics signals in 1 H and 13 C NMR spectra. Its spectrum 1 H NMR showed the presence of singlet at δ 4.19 corresponding to 5H (cyclopentadiene ring of ferrocene) along with two singlets at δ 4.54 (2H) and δ 4.85 (2H) due to the presence of ferrocene ring proton along with the presence of two doublets at δ 7.45 and at δ 7.54 (J = 15.2 Hz) corresponding to trans-olefinic protons. The presence of characteristic signals at δ 162.1 and 187.0 ppm corresponding to the uracil ring carbonyls along with the requisite number of carbons in 13 C NMR spectrum further corroborated the assigned structure
The synthesized conjugates were evaluated for their cytotoxic profiles against human leukemia cell (CCRF-CEM) and human breast adenocarcinoma (MDA-MB-468) cells using MTS-assay, and the results are depicted graphically in Fig. 1 . A standard drug, doxorubicin (Dox) was used as a positive control. A number of compounds exhibited substantial cytotoxicity after 72 h incubation. A closer inspection revealed the dependence of cytotoxicity on the length of alkyl chain introduced as a spacer with a preference for longer chain lengths while the nature of substituents at C-5 position of uracil did not seem to influence the activity profiles. The conjugates, having longer alkyl chain lenghts introduced as spacer, viz. 5e (n = 6); 5f (n = 8); 5j (n = 5); 5k (n = 6); 5p (n = 5); 5q (n = 6), and 5r (n = 8) reduced the proliferation of CCRF-CEM cells by approximately 70% after 72 h against. A similar inspection of the cytotoxic activities of the synthesized conjugates against MDA-MB-468 revealed that most of the conjugates were inactive even after 72 h; the exception being 5a, having an ethyl chain as spacer and 5d, with a pentyl chain reduced the cell proliferation by 59 and 62%, respectively.
Seven of the most potent conjugates viz. 5e, 5f, 5j, 5k, 5p, 5q, 5r were also evaluated for the cytotoxic profiles against normal kidney cell line (LLC-PK1 ATCC CL-101) and the results were compared with doxorubicin. As evident, the conjugates with potent activity against CCRF-CEM cell line did not show any significant toxicity at a concentration of 50 μM after 24 h incubation (Fig. 2) . Furthermore, the compounds were found to be significantly less cytotoxic in non-tumorigenic LLC-PK1 when compared with CCRF-CEM cancer cells after 72 h (Fig. 1) .
Conclusion
In conclusion, a series of uracil-ferrocenyl chalcone conjugates were prepared via Cu-promoted azide alkyne cycloaddition reaction along with an evaluation of their cytotoxic potential against human leukemia and human breast adenocarcinoma cell lines. Structure-activity relationship studies revealed the dependence of cytotoxic efficacy on the length of alkyl chain introduced as linker with a Scheme 1 Synthesis of compounds 5a-r. a Dibromo alkanes (1.2 eq), NaH (1.2 eq), DMF, 60°C, 8 h b NaN 3 , DMF, 60°C, 1 h c CuSO 4 .5H 2 O, Sodium Ascorbate, EtOH:H 2 O, rt, 12 h number of conjugates exhibiting~70% antiproliferative activity against human leukemia (CCRF-CEM) cell line after 72 h. The synthesized conjugates were also found to be significantly less toxic to normal kidney cell line (LLC-PK1, ATCC CL-101).
Associated content
Scanned ( 1 H, 13 C) NMR spectra for the compounds viz. 5f, 5o, 5p. This material is available free of charge via the Internet at http://pubs.rsc.org. Fig. 2 Cytotoxic activity of 5e, 5f, 5j, 5k, 5p, 5q and 5r (50 µM) against normal kidney cell line (LLC-PK1) Fig. 1 Cytotoxic activity of compounds 5a-r (50 µM) on a CCRF-CEM and b MDA-MB-468 cells
